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ABSTRACT 
 
In vitro cell proliferation assays are widely used in pharmacology, molecular biology, and 
drug discovery. Using theoretical modeling and experimentation, we show that current 
antiproliferative drug effect metrics suffer from time-dependent bias, leading to inaccurate 
assessments of parameters such as drug potency and efficacy. We propose the drug-induced 
proliferation (DIP) rate, the slope of the line on a plot of cell population doublings versus time, as 
an alternative, time-independent metric.  
 
MAIN TEXT 
 
Evaluating antiproliferative drug activity on cells in vitro is a widespread practice in basic 
biomedical research1-3 and drug discovery4-6. Typically, quantitative assessment relies on 
constructing dose–response curves7 (Supplementary Note and Supplementary Fig. 1). Briefly, a 
drug is added over a range of concentrations and the effect on the cell population is quantified 
with a metric of choice8. The de facto standard metric is the number of viable cells 72 h after 
drug addition4,6,8,9. Being a single-time-point measurement, we refer to this as a “static” drug 
effect metric. The data is then fit to the Hill equation10, a four-parameter log-logistic function, to 
produce a sigmoidal dose–response curve that summarizes the relationship between drug effect 
and concentration. Parameters extracted from these curves include the maximum effect (Emax), 
the half-maximal effective concentration (EC50), the half-maximal inhibitory concentration (IC50), 
area under the curve (AUC), and activity area (AA)4,6,8,9 (Supplementary Fig. 1 and 
Supplementary Table 1). These are useful for quantitatively comparing various aspects of drug 
activity across drugs and cell lines. 
We contend that dose–response curves constructed using current standard metrics of drug 
effect can result in erroneous and misleading values of drug-activity parameters, skewing data 
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interpretation. This is because they suffer from time-dependent bias, i.e., the metric value varies 
with the time point chosen for experimental measurement. We identify two specific sources of 
time-dependent bias: (i) exponential growth, and (ii) delays in drug effect stabilization. The 
former can lead to erroneous conclusions, e.g., that a drug is increasing in effectiveness over 
time, while the latter requires shifting the window of evaluation to only include data points after 
stabilization has been achieved (Supplementary Fig. 2). 
To overcome this problem of bias, we propose as an alternative drug effect metric the drug-
induced proliferation (DIP) rate11,12, defined as the steady-state rate of proliferation of a cell 
population in the presence of a given concentration of drug. Previously, with related 
approaches, we quantified clonal fitness12 and heterogeneous single-cell fates11 within cell 
populations responding to perturbations. Here, we show that DIP rate is an ideal metric of 
antiproliferative drug effect because it naturally avoids the bias afflicting traditional metrics, it is 
easily quantified as the slope of the line on a plot of cell-population doublings versus time 
(Supplementary Fig. 2), and it is interpretable biologically as the rate of regression or expansion 
of a cell population.  
To theoretically illustrate the consequences of time-dependent bias in standard drug effect 
metrics, we constructed a simple mathematical model of cell proliferation that exhibits the 
salient features of cultured cell dynamics in response to drug (Online Methods, Supplementary 
Note, Supplementary Fig. 3, and Supplementary Table 2). The model assumes that cells 
experience two fates, division and death, and that the drug modulates the difference between 
the rates of these two processes, i.e., the net rate of proliferation. Drug action may occur 
immediately or gradually over time, depending on the chosen parameter values. In all cases, a 
stable DIP rate is eventually achieved, and when calculated over a range of drug concentrations 
a sigmoidal dose–response relationship emerges (Supplementary Note and Supplementary Fig. 
3). 
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We model three scenarios: treatment of a fast-proliferating cell line with a fast-acting drug 
(Fig. 1a), a slow-proliferating cell line with a fast-acting drug (Fig. 1b), and a fast-proliferating 
cell line with a delayed-action drug (Fig. 1c). In each case, we generate simulated growth 
curves in the presence of increasing drug concentrations (Fig. 1, columns 1 and 2) and from 
these produce static dose–response curves by taking cell counts at single time points between 
12h and 120h (Fig. 1, column 3). As expected, in each scenario the shape of the dose–
response curve varies depending on the time of measurement. Consequently, parameter values 
extracted from these curves (EC50 and AA) also vary (Fig. 1, columns 4 and 5). Similar results 
are obtained for an alternative drug effect metric proposed by the U.S. National Cancer 
Institute’s Developmental Therapeutics Program13 (Supplementary Note and Supplementary 
Fig. 4). In contrast, DIP rate, being the slope of a line, is independent of measurement time. 
Using it as the drug effect metric gives a single dose–response curve (Fig. 1, columns 3 and 6) 
and single values of the extracted drug-activity parameters (Fig. 1, columns 4 and 5).  
As a first confirmation of our theoretical findings, we subjected triple-negative breast cancer 
cells (MDA-MB-231) to the metabolic inhibitors rotenone (Fig. 2a) and phenformin (Fig. 2b). 
Using fluorescence microscopy time-lapse imaging11,12,14 (Online Methods), we quantified 
changes in cell number over time for a range of drug concentrations. For both drugs, we 
observe a rapid stabilization of the drug effect (<24h delay) and stable exponential proliferation 
thereafter, reminiscent of the growth dynamics of the theoretical cell lines treated with fast-
acting drugs (Fig. 1a,b). We generated dose–response curves from these data using the 
standard static effect metric and DIP rate for various drug exposure times. Consistent with our 
theoretical results, the shape of the static-based dose–response curve strongly depends on the 
time point at which cell counts are taken, an illustration of time-dependent bias. The DIP rate, on 
the other hand, is free of time-dependent bias and produces a single dose–response curve in 
both cases. 
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These DIP rate-based dose–response curves produce interesting insights (Fig. 2a,b). For 
example, they indicate that while rotenone is much more potent than phenformin (EC50 ≅ 8.5 nM 
versus 25 µM), phenformin is more effective (Emax/E0 ≅ –0.1 versus 0.1). The ordering of 
potencies (rotenone >> phenformin) could have been garnered from the static dose–response 
curves, but not the ordering of efficacies, i.e., the static drug effect metric obscures the crucial 
fact that at saturating concentrations phenformin is cytotoxic (causes cell population regression) 
while rotenone is partially cytostatic (cell populations continue to expand slowly). This 
information is obviously critical to studies assessing drug mechanism of action. This example 
illustrates the perils of biased drug effect metrics and the ability of DIP rate to produce reliable 
dose-response curves from which accurate quantitative and qualitative assessments of 
antiproliferative drug activity can be made. 
To illustrate the confounding effects that a delay in the stabilization of the drug effect can 
have, we examined single-cell derived clones of the lung cancer cell line PC9, which is known to 
be hypersensitive to erlotinib15, an epidermal growth factor receptor (EGFR) kinase inhibitor. 
Consistent with our previous report11, three drug-sensitive PC9-derived clones (DS3, DS4, DS5) 
each respond to 3 µM erlotinib with nonlinear growth dynamics over the first 48–72h, followed 
by stable exponential proliferation thereafter (Fig. 2c). These dynamics are reminiscent of those 
for the theoretical fast-proliferating cell line with a delayed-action drug (Fig. 1c). Due to the delay 
in drug action, all three clones have nearly identical population sizes 72h after drug addition for 
all concentrations considered. The static 72h metric thus produces essentially identical dose–
response curves for all clones (Supplementary Fig. 5). In contrast, dose–response curves based 
on DIP rate make a clear distinction between the clones in terms of their long-term response to 
drug, i.e., erlotinib is cytotoxic (negative DIP rate) for two of the clones but partially cytostatic 
(positive DIP rate) for the other (Fig. 2c).  
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We then investigated the effects of erlotinib and lapatinib (a dual EGFR/human EGFR 2 
(HER2) kinase inhibitor) on HER2-positive breast cancer cells (HCC1954; delay ~48h; Fig. 2d). 
In each case, DIP rate-based dose–response curves produce EC50 values more than five-fold 
larger than their static counterparts, i.e., by the static drug effect metric the drugs appear 
significantly more potent than they actually are. Taken together with the PC9 results (Fig. 2c), 
these data illustrate the importance of accounting for delays in drug action when assessing 
antiproliferative drug activity and further emphasize the ability of the DIP rate metric to produce 
accurate drug-activity parameters and qualitative conclusions about drug-response dynamics.  
Within the last several years, a number of studies have been published reporting drug 
responses for hundreds of cell lines derived from various cancer types4,6,9,16,17 and organ 
sites8,18,19. Raw data are available for the responses of over 1000 cancer cell lines to a panel of 
24 drugs in the Cancer Cell Line Encyclopedia (CCLE)6 and for over 1200 cell lines treated with 
140 drugs in the Genomics of Drug Sensitivity in Cancer (GDSC) project9. These data are 
largely based on static measurements of cell number after 72h of drug exposure, a metric that 
we have shown here contains time-dependent bias. 
To investigate bias in these datasets, we treated four BRAFV600E or D-expressing melanoma 
cell lines with various concentrations of the BRAF-targeted agent PLX4720, an analog of 
vemurafenib. We produced experimental growth curves (Fig. 3a), static- and DIP rate-based 
dose–response curves (Fig. 3b), and extracted IC50 values for each cell line and compared 
these to IC50 values obtained from the CCLE and GDSC data sets (Fig. 3c). In all cases, our 
IC50 values correspond closely to the value from at least one of the public data sets. While in 
three cases the static- and DIP rate-based IC50 values correspond within an order of magnitude, 
in one case (A375) they differ by nearly two orders of magnitude. This discrepancy can be 
traced to a period of complex, non-linear dynamics (brief regression followed by rebound) 
observed for this cell line between 24h and 72h post-drug addition (Fig. 3a). This result is 
particularly intriguing because it shows that, based on DIP rate, this cell line is not much 
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different in terms of drug sensitivity than the other three. Using the biased static drug effect 
metric, however, one would be led to the incorrect conclusion that it is significantly more 
sensitive. It is very likely that cases like this abound within these and other similar data sets16,17 
and illustrates the critical need for new antiproliferative drug effect metrics.  
Current protocols for cell proliferation assays are based on informal ‘rules of thumb’, for 
example, counting cells after 72 h of treatment to ameliorate the impact of complex dynamics 
and delays in drug response. However, these de facto standards have no theoretical basis and, 
as demonstrated here, they suffer from time-dependent bias that leads to erroneous 
conclusions. In light of the widespread applications of cell proliferation assays in oncology, 
pharmacology, and basic biomedical science20 (for example, to assess activity of cytokines, cell 
surface receptors, altered signaling pathways, gene overexpression and silencing, or cell 
metabolic adaptation to varied microenvironmental conditions), it is imperative that the quality of 
the metric for antiproliferative assays be improved. Toward this end, we have proposed DIP rate 
as a viable, unbiased alternative. DIP rate overcomes time-dependent bias by log-scaling cell 
count measurements to account for exponential proliferation and shifting the time-window of 
evaluation to accommodate lag in the action of a drug, changes that do not substantially alter 
experimental design (Supplementary Note and Supplementary Figs. 6–9). Moreover, DIP rate is 
an intuitive, biologically interpretable metric, with a sound basis in theoretical population 
dynamics, which faithfully captures, within a single value, the long-term effect of a drug on a cell 
population. Improving the quality of the metric used in antiproliferative assays has the potential 
to improve success rates in drug discovery and yield more robust gene-drug associations in 
biomarker discovery studies. 
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Figure 1. Theoretical illustration of bias in dose–response curves based on static metrics 
of drug effect. Computational simulations of the effects of drugs on: (a) a fast-growing cell line 
treated with a fast-acting drug; (b) a slow-growing cell line treated with a fast-acting drug; (c) a 
fast-growing cell line treated with a slow-acting drug. In all cases, in silico growth curves, plotted 
in linear (column 1) and log2 (column 2) scale, are used to generate static- (column 3) and DIP 
rate-based (columns 3 and 6) dose–response curves, from which values of EC50 (column 4) and 
activity area (AA; column 5) are extracted. For DIP rate-based values of EC50 and AA, the black 
triangle denotes the first time point used to calculate the DIP rate (i.e., after the drug effect has 
stabilized; see Online Methods); the black dashed line signifies that the value remains constant 
for all subsequent time points. Note that the “response ratio” (column 3) and “direct effect” 
(column 6) versions of the DIP rate-based dose–response curves (Supplementary Fig. 1) 
convey complementary information about the activity of a drug on a cell line (see 
Supplementary Note for further discussion). 
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Figure 2. Experimental illustration of time-dependent bias in dose–response curves for 
drug-treated cancer cells. Population growth curves (log2 scaled) and derived dose–response 
curves (static- and/or DIP rate-based) for (a) MDA-MB-231 triple-negative breast cancer cells 
treated with rotenone; (b) MDA-MB-231 cells treated with phenformin; (c) three single-cell-
derived drug-sensitive (DS) clones of the EGFR mutant-expressing lung cancer cell line PC9 
treated with erlotinib; (d) HCC1954 HER2-positive breast cancer cells treated with erlotinib and 
lapatinib. Data for (a) and (b) are from single experiments with technical duplicates; data in (c) 
are from individual wells for two experiments containing technical duplicates (growth curves) 
and from a single experiment with technical duplicates (dose–response curves); data in (d) are 
sums of technical duplicates from a single experiment (growth curves) and mean values 
(circles) with 95% confidence intervals (gray shading) on the log-logistic model fit (dose–
response curves; n=4, 6 for erlotinib and lapatinib, respectively). 
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Figure 3. Bias in potency metrics from publicly available data sets. (a) Population growth 
curves (log2 scaled) for four select BRAF-mutant melanoma cell lines treated with various 
concentrations of the BRAF inhibitor PLX4720; (b) dose–response curves based on the static 
effect metric (colored lines) and DIP rate (black line); (c) static- (circles) and DIP rate-based 
(triangle+line) estimates of IC50 for each measurement time point. IC50 values obtained from 
public data sets (CCLE: Cancer Cell Line Encyclopedia; GDSC: Genomics of Drug Sensitivity in 
Cancer), based on the static 72h drug effect metric, are included for comparison. The triangle 
denotes the first time point used in calculating the DIP rate and the black line signifies that the 
value remains constant for all subsequent time points. Data shown are from a single experiment 
with technical duplicates. Experiment has been repeated at least twice with similar results.  
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ONLINE METHODS 
Dose–response curve fitting 
All drug-response data (theoretical and experimental) were fit with a four-parameter log-
logistic function (Supplementary Note) using nonlinear least-squares regression21 within the R 
statistical programming environment (http://R-project.org). Fitting was performed using the drm 
function of the drc R library22. Ninety-five percent confidence intervals for each parameter were 
obtained using the delta method assuming asymptotic variance21, as implemented within the 
confint function of the stats R library. EC50 is a fit parameter of the model. IC50 is the 
concentration at which Edrug = E0 / 2 (Supplementary Fig. 1 and Supplementary Table 1), 
independent of the value of Emax, and is obtained using the ED function of the drc library. 
Activity area (AA; Supplementary Fig. 1) is calculated as 
 AA = − 𝐸!"#$,! 𝐸! − 1!!!! 𝑁       (1) 
 
where Edrug,i is the value of the effect metric at the i-th drug concentration and N is the total 
number of concentrations considered. 
 
A simple two-state model of drug action on an exponentially proliferating cell population 
We assume that cells can exist in two states, a “no-drug” and a “drug-saturated” state, and 
that cells in each state can experience two fates, division and death, with kinetic rate constants 
that are characteristic of the state, i.e., reflecting the effect of the drug (visual representation of 
the model is provided in Supplementary Fig. 3a). In the presence of drug, cells can transition 
from the no-drug to the drug-saturated state at a rate proportional to the concentration of drug. 
Reverse transitions occur at a rate independent of drug. If Cell is the number of cells in the no-
drug state and Cell* is the number of cells in the drug-saturated state, then the temporal 
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dynamics of the drug-treated cell population is described by the following pair of coupled 
ordinary differential equations, 
 !"#$$!" = 𝑘!"# − 𝑘!"#$! − 𝑘!"𝐷𝑟𝑢𝑔 ∙ 𝐶𝑒𝑙𝑙 + 𝑘!"" ∙ 𝐶𝑒𝑙𝑙∗     (2) !!"##∗!" = 𝑘!"#∗ − 𝑘!"#$!∗ − 𝑘!"" ∙ 𝐶𝑒𝑙𝑙∗ + 𝑘!" ∙ 𝐷𝑟𝑢𝑔 ∙ 𝐶𝑒𝑙𝑙    (3) 
 
where kdiv (kdiv*) and kdeath (kdeath*) are the rate constants for cellular division and death, 
respectively, in the no-drug (drug-saturated) state, Drug is the drug concentration, kon is the rate 
constant for the transition from the no-drug to the drug-saturated state, and koff is the rate 
constant for the reverse transition. 
At a given drug concentration (assumed to be constant, i.e., drug is neither consumed, 
removed, nor degraded), a population of cells will eventually reach a dynamic equilibrium in 
terms of the number of cells in each state. The effective DIP rate of a cell population is then the 
weighted average of the net proliferation rates (i.e., the difference between the division and 
death rate constants) of the two individual states (Supplementary Fig. 3b). With increasing drug 
concentration, the equilibrium shifts increasingly towards the drug-saturated state, 
asymptotically approaching 100% occupancy. The result is a sigmoidal dose–response 
relationship between DIP rate and drug concentration (Supplementary Fig. 3c,d). If the values of 
the rate constants governing the interconversion between the no-drug and drug-saturated state 
(kon and koff) are “large” (effectively infinite), then the dynamic equilibrium between states is 
achieved immediately upon drug addition. This is known as the partial equilibrium assumption 
(PEA)23,24. Mathematically, the PEA asserts that 
 𝑘!" ∙ 𝐷𝑟𝑢𝑔 ∙ 𝐶𝑒𝑙𝑙 = 𝑘!"" ∙ 𝐶𝑒𝑙𝑙∗        (4) 
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Under this assumption, an analytical solution for the total number of cells, CellT = Cell + Cell*, 
can be obtained as a function of time, 
 
ln !"##!(!)!"##!(!) =  !!""/!!" !!"#!!!"#$! !!"#$ !!"#∗ !!!"#$!∗!!""/!!"!!"#$ ∙ 𝑡     (5)  
 
where CellT(0) is the initial number of cells. All theoretical results shown in Figure 1a,b were 
obtained using equation (5). For the results in Figure 1c and Supplementary Figure 4, numerical 
integration of equations (2) and (3) was necessary since the values of kon and koff were set such 
that the PEA does not hold (Supplementary Table 2), i.e., there is a delay in the stabilization of 
the drug effect. Numerical integration was performed in R using the deSolve package25. For 
further details of the model, see Supplementary Note; for all parameter values used in this work, 
see Supplementary Table 2. 
 
Cell lines 
The PC9 cell line was originally obtained from William Pao (Vanderbilt University). WM115 
cells were from Meenhard Herlyn (Wistar Institute). All other cell lines were obtained from the 
American Type Culture Collection (www.atcc.org). All cell lines are regularly tested for 
mycoplasma using a PCR-based method (MycoAlert, Lonza, Allendale, NJ) and any positive 
cultures are immediately discarded. Cell line authentication is provided by ATCC. Authenticity of 
PC9 and WM115 have not been verified. 
 
Time-lapse fluorescence microscopic imaging 
Time-lapse fluorescence microscopy of cells expressing histone H2B conjugated to 
monomeric red fluorescent protein (H2BmRFP) to facilitate automated image analysis for 
identifying and quantifying individual nuclei was performed as previously described11,12,14. 
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Briefly, cells are engineered to express H2BmRFP using recombinant, replication-incompetent 
lentiviral particles and flow sorted for the highest 20% intensity. Cells are seeded at ~2,500 cells 
per well in 96-well imaging microtiter plates (BD Biosciences) and fluorescent nuclei are imaged 
using a BD Pathway 855 with a 20× objective in 3×3 montaged images per well at ~15 min 
intervals for 5 days. Alternatively, fluorescent cell nuclei are imaged twice daily using a 
Synentec Cellavista High End with a 20× objective and tiling of nine images. DIP rate-based 
dose–response curves shown in Figure 2c were generated from a single experiment performed 
at the Vanderbilt High-Throughput Screening Core on a Molecular Devices ImageXpress using 
similar imaging parameters. The experiment had two technical replicates per condition and 
images were obtained at 0, 24, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96,100,104,108, 
and 112 hours after addition of erlotinib at each of eight different concentrations or dimethyl 
sulfoxide (DMSO) control.  
 
Other statistical considerations and code availability 
Estimates of DIP rate are determined within an experiment using the sum of cells across all 
technical replicates at a given time point and obtaining the slope of a linear model of 
log2(cell number) ~ time for time points greater than the observed delay. Minimum 
delay time is estimated by visual inspection of log-growth curves for the time at which they 
become approximately linear (for an automated method of estimating the stabilization time 
point, see Supplementary Note and Supplementary Figs. 6 and 7). All data analysis was 
performed in R (version 3.2.1) and all raw data and R analysis code is freely available at 
github.com/QuLab-VU/DIP_rate_NatMeth2016. 
 
Publicly available data sets 
Drug-response data were obtained from the Genomics of Drug Sensitivity in Cancer (GDSC) 
project4,9 website at ftp://ftp.sanger.ac.uk/pub/project/cancerrxgene/releases/release-
19 
5.0/gdsc_drug_sensitivity_raw_data_w5.zip and from the Cancer Cell Line Encyclopedia 
(CCLE)6 website at http://www.broadinstitute.org/ccle/ in the data file 
CCLE_NP24.2009_Drug_data_2015.02.24.csv (user login required). 
 
Methods-only References  
21. Seber, G. A. F. & Wild, C. J. Nonlinear Regression. (John Wiley & Sons, Inc., 2005). 
doi:10.1002/0471725315 
22. Ritz, C. & Streibig, J. C. Bioassay analysis using R. Journal of Statistical Software (2005). 
23. Cornish-Bowden, A. Fundamentals of Enzyme Kinetics. (Wiley-Blackwell, 2012). 
24. Rein, M. The Partial-Equilibrium Approximation in Reacting Flows. Physics of Fluids A - 
Fluid Dynamics 4, 873–886 (1992). 
25. Soetaert, K., Petzoldt, T. & Setzer, R. W. Solving Differential Equations in R: Package 
deSolve. Journal of Statistical Software 33, 1–25 
  
20 
SUPPLEMENTARY INFORMATION: “An unbiased metric of antiproliferative drug effect in vitro” 
 
TABLE OF CONTENTS 
 
SUPPLEMENTARY NOTE 
 DOSE–RESPONSE CURVES AND THE HILL EQUATION 
 SIMPLE TWO-STATE MODEL OF DRUG CONCENTRATION-DEPENDENT 
FRACTIONAL PROLIFERATION 
 CELL PROLIFERATION ASSAY DEVELOPED BY THE NATIONAL CANCER 
INSTITUTE DEVELOPMENTAL THERAPEUTICS PROGRAM 
 PRACTICAL CONSIDERATIONS FOR USING THE DIP RATE METRIC IN HIGH-
THROUGHPUT SCREENING ASSAYS 
   Duration of the experiment 
   Drug additions and media changes 
   Range of drug concentrations 
   Cell counting methodology 
   Frequency of sampling 
   Aggregation of data from technical and biological replicates 
   Collected data structure 
   Automated estimation and statistical confidence of DIP rate 
   Variations around a mean cell seeding density and measurement time 
   Variations in mean cell seeding density 
 PROTOCOL FOR GENERATING DOSE–RESPONSE CURVES USING DIP RATE AS 
THE DRUG EFFECT METRIC 
 
SUPPLEMENTARY RESULTS 
 SUPPLEMENTARY FIGURE 1 | DIFFERENT FORMULATIONS OF THE DOSE–
RESPONSE CURVE 
 SUPPLEMENTARY FIGURE 2 | FAST-ACTING DRUGS, SLOW-ACTING DRUGS, AND 
DIP RATE 
 SUPPLEMENTARY FIGURE 3 | TWO-STATE MODEL OF FRACTIONAL 
PROLIFERATION PREDICTS A SIGMOIDAL RELATIONSHIP BETWEEN 
PROLIFERATION RATE AND DRUG CONCENTRATION. 
 SUPPLEMENTARY FIGURE 4  | THEORETICAL ILLUSTRATION OF BIAS IN DOSE–
RESPONSE CURVES BASED ON THE NCI DTP DYNAMIC DRUG EFFECT 
METRIC 
 SUPPLEMENTARY FIGURE 5 | STATIC-BASED DOSE–RESPONSE CURVES FOR 
PC9 PARENTAL CELLS AND SUBCLONES TREATED WITH ERLOTINIB 
 SUPPLEMENTARY FIGURE 6  | AUTOMATED ESTIMATION OF DIP RATE FROM 
CELL COUNT DATA 
 SUPPLEMENTARY FIGURE 7  | EFFECTS OF SAMPLING FREQUENCY ON 
AUTOMATED DIP RATE ESTIMATION 
 SUPPLEMENTARY FIGURE 8 | THEORETICAL EFFECTS OF VARIATIONS AROUND 
A MEAN CELL SEEDING DENSITY ON THE STATIC EFFECT METRIC AND 
RESPONSE RATIO 
 SUPPLEMENTARY FIGURE 9 | EFFECTS OF VARIATIONS IN MEAN CELL SEEDING 
DENSITY ON DIP RATE ESTIMATION 
 SUPPLEMENTARY TABLE 1 | GLOSSARY OF TERMS 
 SUPPLEMENTARY TABLE 2 | RATE PARAMETER VALUES USED IN THIS WORK 
 
SUPPLEMENTARY REFERENCES  
21 
SUPPLEMENTARY NOTE 
 
Dose–response curves and the Hill equation 
 
In its most general form, the Hill equation can be written as  𝑦 = !!!!!!! ,         (S1) 
where x is the independent variable, y is the dependent variable, C is a constant that when 
equal to x results in a value of y = 1/2, and h is the Hill coefficient (note that C and h can both be 
positively or negatively valued). For cell proliferation assays, where Edrug is the effect induced by 
drug at concentration drug, Emax is the maximum achievable drug effect, and E0 is the effect in 
the absence of drug, dose-response curves can be constructed using equation (S1) with x as 
the drug concentration, y as the ratio (Edrug – Emax) / (E0 – Emax), the constant C > 0 as the “half-
maximal effective concentration,” denoted as EC50, and h > 0 (assuming drug inhibits cell 
population growth), i.e., !!"#$!!!"#!!!!!"# =  !"!"!!"!"!!!"#$!.       (S2) 
Equation (S2) is known as a four-parameter log-logistic function, the four parameters being 
Emax, E0, EC50, and h. Besides these four, additional drug-activity parameters that can be 
extracted from these curves include IC50 (the half-maximal inhibitory concentration), area under 
the curve (AUC), and activity area (AA; the inverse of AUC)1-6 (see Supplementary Table 1 for 
definitions of these and other relevant terms). These parameters can be used to compare 
various aspects of drug activity quantitatively across drugs and cell lines. We refer to equation 
(S2) (reproduced in Supplementary Fig. 1a) as the “scaled” form of the dose-response curve 
because the y-axis values are scaled between 0 and 1. 
 
Dose–response curves are generally plotted with drug concentrations along the x-axis in 
log10 scale in order to easily visualize a broad range of concentrations. In this view, we can 
show that the Hill coefficient h is inversely proportional to the slope of the curve at the EC50 by 
noting that log10(x) = ln(x) / ln(10) and calculating the derivative of equation (S2) with respect to 
log10(x), !"!log!"! = !"!" ∙ !"!log!"! = ! !" !" !!!!!!!!!! ! .       (S3) 
Evaluating this at x = C gives !"!log!"! !!! = ! !" !"! ℎ.        (S4) 
Hence, the larger the value of h the steeper the dose–response curve at the EC50, and vice 
versa1.  
 
Furthermore, we define the IC50 (half-maximal inhibitory concentration) as the concentration 
of drug at which Edrug = E0 / 2 (Supplementary Table 1). Substituting this into equation (1) of the 
main text, setting drug = IC50, and rearranging gives 
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𝐼𝐶!"! = !.!∙!!!.!∙!!!!!"# ∙ 𝐸𝐶!"! .       (S5) 
We see, therefore, that if Emax < 0 then IC50 < EC50 (Supplementary Fig. 1), and vice versa. 
Importantly, we also see that IC50 is not defined if Emax ≥	E0/2, which makes intuitive sense. 
Note that when cell number after a specified period of drug exposure is used as the drug effect 
metric (the standard “static” metric), Emax is always ≥ 0. However, for dynamic metrics such as 
DIP rate, Emax can be positive or negative. 
 
In practice, E0 and Emax, along with EC50 and h, are treated as adjustable parameters that 
can be estimated based on a numerical fit to experimental drug-response data using nonlinear 
least-squares regression. To accomplish this, equation (S2) is rearranged to solve for Edrug, 
which we refer to as the “direct effect” form of the dose–response curve (Supplementary Fig. 
1b). In the main text, we argue that a valuable characteristic of the DIP rate is that it is directly 
interpretable from a biological perspective. We support this claim by showing direct-effect DIP 
rate-based dose–response curves in column 6 of Figure 1. These can be used to directly infer 
the characteristics of the theoretical growth curves (e.g., proliferation rates in the absence of 
drug, DIP rates at saturating drug concentrations) shown in columns 1 and 2 of Figure 1. In 
general, we suggest that all DIP-rate based drug-response data be reported and stored (e.g., in 
public databases) in this form. 
 
In contrast to the DIP rate, static drug effect metrics (e.g., cell number 72h after drug 
exposure) do not have any biological meaning except with respect to a reference value, such as 
untreated control. As such, static dose–response curves are usually displayed in terms of the 
“response ratio” Edrug/E0. The equation for this form of the dose–response curve is obtained by 
simply dividing the direct-effect form by E0 (Supplementary Fig. 1c). In Figures 1–3 of the main 
text and Supplementary Figures 4 and 5, we show numerous examples of dose–response 
curves plotted in terms of response ratios, both for traditional drug effect metrics and DIP rate. 
This allows us to directly compare traditional and DIP rate-based dose–response curves on the 
same plot. Furthermore, in the case of DIP rate, direct-effect and response-ratio dose–response 
curves convey complementary, but distinct, information, which may be important for interpreting 
drug effects within different contexts. For example, in Figure 1, the fast- and slow-proliferating 
cell lines treated with fast-acting drugs exhibit identical response-ratio dose–response curves 
(by construction; see Supplementary Table 2). This indicates the same dose-dependent drug 
activity in these cell lines despite the substantially different basal rates of proliferation and rates 
of cell loss at high drug concentrations, evident in their direct-effect dose–response curves. 
When assessing drug activity across cell lines, in particular, both sets of information are 
important. We refrain, therefore, from advocating for one form of the dose–response curve over 
the other. Note, however, that response ratios are easily calculated from the information 
contained within direct-effect dose–response curves, which is why we advocate storing drug-
response data in this form. 
 
Simple two-state model of drug concentration-dependent fractional proliferation 
 
Substantial evidence exists that anticancer drugs affect cultures of solid tumor-derived 
cancer cells by both inducing cell death and elongating cell cycle times7,8. We refer to the 
concept that the dynamics of drug-treated cell populations are a combined effect of multiple 
different cell fates (e.g., cell division, death, and survival) as “fractional proliferation” (see 
Supplementary Table 1). We previously described a Quiescence-Growth (QG) mathematical 
model that assumes that drugs can affect the rates of three different cell fates: division, death, 
and entry into quiescence8. We used the model to consolidate drug-induced single cell fate 
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decisions with cell population dynamics for several cell lines treated with a variety of drugs8. 
However, the model does not describe the relationship between the rates of cell fates and the 
concentration of drug. We therefore modified the QG model, as described in detail below, to 
provide a mechanistic basis for the observed log-logistic relationship between drug 
concentration and steady-state rate of cell proliferation (i.e., DIP rate). 
  
As described in Online Methods, we assume that cells can exist in two states: a “no-drug” 
and a “drug-saturated” state. Cells within each state can divide and die at rates that are 
characteristic of the state. Furthermore, cells can transition between the two states, with the rate 
of transition from the no-drug to the drug-saturated state being dependent upon drug 
concentration (Supplementary Fig. 3a). Since the effect of an anticancer drug is to reduce the 
net rate of proliferation of a cell population, we impose that the proliferation rate of the no-drug 
state be larger than that of the drug-saturated state (Supplementary Fig. 3b). Defining Cell and 
Cell* to be the populations of cells in the no-drug and drug-saturated states, respectively, the 
model can be written in kinetic terms as 𝐶𝑒𝑙𝑙 !!"# 𝐶𝑒𝑙𝑙 + 𝐶𝑒𝑙𝑙        (S6) 𝐶𝑒𝑙𝑙 !!"#$! ∅         (S7) 𝐶𝑒𝑙𝑙 + 𝐷𝑟𝑢𝑔 !!" 𝐶𝑒𝑙𝑙∗ + 𝐷𝑟𝑢𝑔       (S8) 𝐶𝑒𝑙𝑙∗ !!"" 𝐶𝑒𝑙𝑙         (S9) 𝐶𝑒𝑙𝑙∗ !!"#∗ 𝐶𝑒𝑙𝑙∗ + 𝐶𝑒𝑙𝑙∗        (S10) 𝐶𝑒𝑙𝑙∗ !!"#$!∗ ∅         (S11) 
where ∅  represents cell death (the null state) and all rate constants are as illustrated in 
Supplementary Figure 3a. 
 
Assuming continuous and deterministic dynamics, the time course of a drug-treated cell 
population is described by a coupled set of ordinary differential equations (ODEs), which can be 
derived directly from reaction set (S6)–(S11),  !"#$$!" = 𝑘!"# − 𝑘!"#$! − 𝑘!" 𝐷𝑟𝑢𝑔 ∙ 𝐶𝑒𝑙𝑙 + 𝑘!"" ∙ 𝐶𝑒𝑙𝑙∗,   (S12) !!"##∗!" = 𝑘!"#∗ − 𝑘!"#$!∗ − 𝑘!"" ∙ 𝐶𝑒𝑙𝑙∗ + 𝑘!" ∙ 𝐷𝑟𝑢𝑔 ∙ 𝐶𝑒𝑙𝑙.   (S13) 
Equations (S12) and (S13) are presented as equations (2) and (3) in the main text, respectively. 
In general, these equations must be solved numerically. However, if the rate constants kon and 
koff that govern the transitions between the no-drug and drug-saturated states are “large” 
(effectively infinite), then a solution can be obtained analytically under the partial equilibrium 
assumption9 (PEA). The PEA amounts to setting the rates of reactions (S8) and (S9) equal to 
each other, i.e., 𝑘!" ∙ 𝐷𝑟𝑢𝑔 ∙ 𝐶𝑒𝑙𝑙 = 𝑘!"" ∙ 𝐶𝑒𝑙𝑙∗.       (S14) 
Equation (S14) is presented as equation (4) in the main text. If we define the total cell 
population as 
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𝐶𝑒𝑙𝑙! ≡ 𝐶𝑒𝑙𝑙 + 𝐶𝑒𝑙𝑙∗,        (S15) 
then we can obtain expressions for the no-drug and drug-saturated cell populations as a 
function of the total cell population by substituting equation (S15) into equation (S14) and 
rearranging, 
𝐶𝑒𝑙𝑙 =  !!""!!" !!""!!" !!"#$ ∙ 𝐶𝑒𝑙𝑙!,       (S16) 𝐶𝑒𝑙𝑙∗ =  !"#$!!""!!" !!"#$ ∙ 𝐶𝑒𝑙𝑙!.       (S17) 
Summing equations (S12) and (S13) gives a single ODE describing the temporal dynamics of 
the total cell population, !!"##!!" = !"#$$!" + !!"##∗!" = 𝑘!"# − 𝑘!"#!! ∙ 𝐶𝑒𝑙𝑙 +  𝑘!"#∗ − 𝑘!"#$!∗ ∙ 𝐶𝑒𝑙𝑙∗. (S18) 
Substituting equations (S16) and (S17) into equation (S18) and rearranging gives 
!!"##!!" =  !!""!!" !!"#!!!"#$! ! !"#$ !!"#∗!!!"#$!∗ !!""!!" !!"#$ ∙ 𝐶𝑒𝑙𝑙!,    (S19) 
which can be solved analytically by separation of variables, 
ln !"##!!"##! ! = !!""!!" !!"#!!!"#$! ! !"#$ !!"#∗!!!"#$!∗ !!""!!" !!"#$ ∙ 𝑡.    (S20) 
Equation (S20) is presented as equation (5) in the main text. 
 
The DIP rate is defined as the slope of the line on a semi-log2 plot of cell number vs. time. 
Therefore, under the PEA, the DIP rate for our model is 
𝐷𝐼𝑃 =  !!" ! ∙ !!""!!" !!"#!!!"#$! ! !"#$ !!"#∗!!!"#$!∗ !!""!!" !!"!" .     (S21) 
At zero drug concentration, equation (S21) reduces to 𝐷𝐼𝑃! = !!" ! ∙ 𝑘!"# − 𝑘!"#$! .       (S22) 
At maximum (infinite) drug concentration, equation (S21) reduces to 𝐷𝐼𝑃!"# = !!" ! ∙ 𝑘!"#∗ − 𝑘!"#$!∗ .      (S23) 
With DIP, DIP0, and DIPmax as Edrug, E0, and Emax, respectively, equation (S2) describing the 
dose-response curve can be rewritten as  !"#!!"#!"#!"#!!!"#!"# = !"!"!!"!"! !!"#$!.       (S24) 
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Substituting equations (S21)–(S23) into equation (S24) and rearranging gives 
!!""!!"!!""!!" !!"#$   = !"!"!!"!"! !!"#$!.       (S25) 
Thus, we see that under the PEA our model predicts a sigmoidal DIP rate-based dose-response 
curve with  𝐸𝐶!" = !!""!!"          (S26) 
and h = 1 (Supplementary Fig. 3c). We can now obtain an expression for the DIP rate in terms 
of DIP0, DIPmax, and EC50 by substituting equations (S22), (S23), and (S26) into equation (S21) 
and rearranging, 𝐷𝐼𝑃 = !!" ! ∙ !"!"∙!"#!!!"#$∙!"#!"#!"#$!!"!" .      (S27) 
Even in cases where the PEA does not hold, our two-state model (S6)–(S11) predicts a 
sigmoidal relationship between DIP rate and drug concentration, although not exactly of the Hill 
form (Supplementary Fig. 3d). The curve must be obtained in this case through numerical 
integration of equations (S12) and (S13), as an analytical solution is not possible. 
 
Cell proliferation assay developed by the National Cancer Institute Developmental 
Therapeutics Program 
 
An alternative effect metric that is sometimes used in cellular proliferation assays is the 
difference between cell number after a specified period of drug exposure and cell number at the 
time of drug addition1,10-13. A protocol for generating dose–response curves based on this metric 
has been developed by the U.S. National Cancer Institute’s Developmental Therapeutics 
Program10,11 (NCI DTP).  The NCI DTP has been performing in vitro analyses of therapeutic 
compounds on a panel of 60 cancer cell lines (the NCI60) for several decades10. This program 
has screened thousands of compounds for their anticancer properties, of which the U.S. Federal 
Drug Administration has licensed dozens as clinical anticancer agents. The approach for 
characterizing anticancer drug response uses an indirect assay of cell counts based on 
spectrophotometric absorbance readings (described in detail at 
https://dtp.cancer.gov/discovery_development/nci-60/methodology.htm). If the mean 
absorbance of the treated sample after a specified period of drug exposure, Ti, is greater than 
or equal to the mean absorbance on day zero, Tz, then the response ratio is calculated as (Ti – 
Tz) / (C – Tz), where C is the absorbance of the control-treated cells at the same time point as 
Ti. However, if Ti < Tz, then the response ratio is calculated as (Ti – Tz) / Tz. In the terminology 
used in this paper, Ti – Tz is the drug effect metric and it is “dynamic” because it is based on 
measurements at more than one time point (Supplementary Table 1). 
 
The NCI DTP promotes its ability to characterize compounds for their differential or selective 
patterns of drug sensitivity, generally assessed by metrics of potency, across the panel of 
cancer cell lines14. In early work describing the development of the screening assay 
methodology, it was noted that dose–response data was strongly time dependent, such that “the 
magnitude of measured drug sensitivity in a given cell line is primarily dependent upon culture 
[and drug exposure] duration.”14 However, because the NCI DTP metric is based on direct cell 
counts (not log scaled) and does not account for delays in the action of the drug, it is subject to 
the same sources of time-dependent bias that afflict the standard static effect metric (Figs. 1-3 
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of the main text). To demonstrate this, in Supplementary Figure 4a we provide a visual 
illustration of the NCI DTP dynamic metric applied to the population growth curve at 630 nM 
drug concentration from Figure 1c of the main text. We see immediately from this plot the 
confounding effects that bias can have on this metric: depending on when the cell count 
measurement is taken, the drug could be interpreted as being partially cytostatic (<96h), fully 
cytostatic (96h), or cytotoxic (>96h). We further quantify the effects of bias in Supplementary 
Figure 4b, where we generate dose–response curves over a range of measurement time points. 
As with the static effect metric (Fig. 1), the shape of the NCI DTP-based curve strongly depends 
on the chosen measurement time point. In light of this fact, we caution against using the NCI 
DTP approach to infer specific biological activities of drugs, contrary to recent reports in the 
literature1,12,15,16. 
 
Practical considerations for using the DIP rate metric in high-throughput screening 
assays 
 
The following issues, related to both experimental design and data analysis, should be 
considered when adopting DIP rate as a standard drug effect metric in high-throughput 
screening assays. 
 
Duration of the experiment 
The recommended total assay duration is seven days since, in most cases, we observe 
stabilization of the DIP rate within this time frame. With modern environmentally controlled 
microscopes, these assays are easily set up and automated with robotics. It is also possible to 
perform longer-term assays if desired, e.g., to confirm DIP rate stability over longer time scales. 
Care should be taken, however, that cell density does not exceed 70% well surface area, as this 
can impact population size-independent drug action. 
 
Drug additions and media changes  
The procedure in use in our laboratory involves seeding cells into multiwell plates, allowing 
them to adhere and/or acclimate for 16–24h, and then adding drug-containing fresh medium 
(defined as time zero). After 72h, medium is replaced with fresh drug-containing medium and 
the assay is continued for another 72h. 
 
Range of drug concentrations  
Published EC50 or IC50 values, if available, are a good starting point for estimating the range 
of concentrations to be used (despite the potential bias in their values, as illustrated in this 
paper). A wide range around that value (e.g., four-fold dilutions for a total of eight drug 
concentrations) should span the relevant range in many cases. It is also possible to use 10-fold 
dilutions to cover a broader range, e.g., if published EC50 or IC50 values are not available. To 
minimize off-target effects, we typically use concentrations below the maximum drug solubility in 
aqueous buffers. 
 
Cell counting methodology 
A variety of cell counting methods can be employed. In our experience, direct cell counting 
from fluorescence microscopy images of cells with labeled nuclei is ideal. Individual nuclei are 
automatically counted by automated image segmentation from digital time series images stored 
by a computerized microscope. Other means of labeling cells, or even unlabeled cells, can be 
used, although this may place more demands on automated cell counting. Indirect cell counting 
via fluorescence intensity measurements, such as CellTiterGlo, is also possible by implementing 
a scheme of replicate plates treated in parallel and harvested at different time points. 
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Frequency of sampling 
In part, the frequency of cell counting is dictated by throughput (i.e., large numbers of plates 
may require accommodation of longer handling times). To test the robustness of our automated 
DIP rate estimation algorithm (see below) to variations in sampling frequency, we calculated 
stabilization times and DIP rates from the complete DS3 data set (n=113) and from successively 
subsampled versions of the data set (n=57, 29, 15 and 8; Supplementary Fig. 7). The 
stabilization times obtained from all of these data sets fell within a 10h window (68–77h). DIP 
rates for all data sets with ≥15 data points varied by less than 1%; the DIP rate value from the 
smallest data set (n=8) was still within 15% of the value obtained from the complete data set. 
These results indicate that obtaining 2–3 images per day (8–12h intervals) is likely sufficient in 
many cases to obtain reasonable estimates of drug effect stabilization times and DIP rates. 
 
Aggregation of data from technical and biological replicates  
Technical replicates (multiple wells in a plate) are unnecessary if sufficient numbers of cells 
can be quantified. However, if technical replicates are generated, the cell counts at each time 
point should be summed rather than averaged to reduce bias introduced by replicates with 
fewer cells. For biological replicates (separate repeat experiments), we calculate the mean DIP 
rate over all replicates. 
 
Collected data structure 
Cell count data is structured as a seven-column matrix, where the columns are:  (1) time of 
measurement, (2) cell count, (3) cell line ID, (4) drug name, (5) drug concentration, (6) well 
number, and (7) date. This structured data can be sent directly to the automatic DIP rate 
estimation algorithm (next subsection) to generate DIP rate-based dose–response curves. 
 
Automated estimation and statistical confidence of DIP rate  
As discussed in the main text, DIP rate is defined as the rate of growth of a cell population at 
steady state, i.e., after the effect of a drug (or any perturbagen) has stabilized. On a plot of cell 
population doublings vs. time, a stabilized drug effect corresponds to a sustained linearity of the 
growth curve. In high-throughput screening assays, computational algorithms that can detect 
drug effect stabilization and calculate DIP rates automatically from cell count data are 
necessary. To identify the optimal range of data over which to calculate DIP rate, we present 
here an algorithm using two commonly applied metrics of linear model fitting: adjusted R2 and 
root-mean-squared error (RMSE). Adjusted R2 quantifies how much the change in cell number 
can be explained by changes in time, whereas RMSE is a metric of how close the measured cell 
numbers are to values predicted by the linear model fit17. Our approach is to first fit a linear 
model to all data points from a time course and calculate adjusted R2 and RMSE values. We 
then progressively remove data points from the beginning of the time course, obtaining new 
model fits and recalculating the adjusted R2 and RMSE values until five data points remain (for a 
five-day experiment where cell counts are acquired every 12h, this amounts to about half the 
data points). DIP rate stabilization can then be defined either as (1) the time point at which the 
adjusted R2 value is at its maximum, i.e., when time and change in log2 cell number are most 
highly correlated, or (2) the time point at which the derivative of the RMSE curve (fit with a 
polynomial) first reaches zero (within a defined tolerance), i.e., the earliest time point for which 
RMSE is not significantly improved by exclusion of this point. To demonstrate the effectiveness 
of this approach, in Supplementary Figure 6 we apply it to the PC9 subline data shown in Figure 
2c of the main text. Both the adjusted R2 and RMSE metrics produce similar values of 
stabilization times and DIP rates for each subline (DS3, DS4, DS5). Stabilization times are 
within a 10h window for DS5 and a 5h window for DS3 and DS4; DIP rates are within 0.001 
doublings h-1 for all sublines. Importantly, all PC9 sublines (including others not shown) 
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demonstrate a stabilized DIP rate by 72h, justifying our use of this time point in the analyses 
presented in the main text. Source code implementing this approach (dipDRC.r) is freely 
available at github.com/QuLab-VU/DIP_rate_NatMeth2016.    
 
Variations around a mean cell seeding density and measurement time 
Variations in the number of cells seeded per well are inevitable in high-throughput assays, 
even when using automated high-precision robotic platforms18. Because cell populations grow 
exponentially, the effects of these variations amplify over time and can significantly affect the 
calculated values of drug effect metrics and extracted drug-response parameters, such as 
potency and efficacy. Variability in the time point at which cell count measurements are acquired 
can have a similar effect. The consequences of these sources of variability can be quantified by 
considering the basic exponential growth formula, 
 𝑋(𝑡) = 𝑋!𝑒!",         (S28) 
 
where X(t) is the cell count at time t, X0 is the initial cell count, and k is the exponential growth 
rate, which is proportional to the DIP rate d=k/ln(2) (i.e., DIP rate is defined on a log2 basis and 
has units of [doublings/time]). From equation (S28), we see immediately that k, and hence d, is 
completely independent of the initial cell count and the measurement time point. DIP rate is thus 
unaffected by any variations in these quantities, assuming that intrinsic stochastic effects are 
minimal (see below). This quality of DIP rate makes it particularly well suited as a standard drug 
effect metric.  
 
The same cannot be said for X(t), which we refer to in the main text as the traditional static 
drug effect metric. If we assume that the initial cell count, X0, is distributed according to a normal 
(Gaussian) distribution with mean µ and variance σ2, denoted as 
 𝑋! ~ N (𝜇,𝜎!),          (S29) 
 
and we assume that the sampling time t is a constant 𝑡, then the final cell count is also normally 
distributed according to 
 𝑋 𝑡  ~ N (𝑒!!𝜇, 𝑒!!!𝜎!).        (S30) 
 
We see, therefore, that in the absence of variations in the measurement time, variability in the 
seeding density broadens the distribution of final cell counts by a constant factor that increases 
exponentially with the intrinsic growth rate of the cell population and with the measurement time 
point. In practice, X(t) is almost always considered in terms of a ratio with respect to untreated 
control, a quantity that we refer to as the “response ratio.” The control value is often taken as 
the mean cell count at time t from N (typically <10) control experiments, i.e., 
 𝑋! 𝑡 = 𝑋! 𝑡!!!! 𝑁,        (S31) 
 
where the subscript c denotes “control.” Assuming that the mean and variance in the seeding 
density in the control experiments is equivalent to that in drug, we can use equations (S30) and 
(S31), with 𝑋 𝑡 = 𝑋! 𝑡  and k=kc, to derive the distribution 
 𝑋! 𝑡  ~ N (𝑒!!!𝜇, 𝑒!!!!𝜎!/𝑁).       (S32) 
 
29 
The response ratio is thus distributed according to the ratio of the two normal distributions in 
equations (S30) and (S32), which we write as  
 ! !!! !  ~  N (!!!!,!!!!!!)N (!!!!!,!!!!!!!/!).        (S33) 
 
An analytical expression for the distribution of the ratio of two normal random variables has 
been presented by Hinkley19.  
 
In the case of variability in the measurement time, if we assume that t is normally distributed, 
 𝑡~ N (𝜇! ,𝜎!!),          (S34) 
 
then the exponential term in equation (S28) is no longer a constant, but is distributed according 
to a log-normal distribution, 
 𝑒!"~ lnN (𝑘𝜇! , 𝑘!𝜎!!).         (S35) 
 
From equation (S28), the final cell count X(t) is therefore distributed according to the product of 
a normally distributed random variable (equation S29) and a log-normally distributed random 
variable (equation S35). This is known as a normal-log-normal (NLN) mixture distribution20. 
Since an analytical expression does not exist for the NLN distribution, we employ numerical 
simulation to obtain estimates for the distributions of X(t), <Xc(t)>, and the response ratio. 
 
In Supplementary Figure 8, we show results of our theoretical analysis of the effects of 
variability in seeding density and measurement time on the traditional static drug effect metric. 
We use the same two-state model as in the main text (described above) with the “fast 
proliferating / fast acting” parameter set (Supplementary Table 2). All simulations were 
performed deterministically using a standard ODE integrator211. In Supplementary Figure 8a, 
we show 100 simulated time courses each for untreated and drug-treated (3 nM) cell 
populations. Because the simulations are deterministic (no intrinsic noise effects), we normalize 
the initial cell counts to the mean, i.e., we sample from the distribution 
 𝑋! 𝜇~ N (1,𝜎! 𝜇!),         (S36) 
 
with standard deviation σ/µ=0.1 (this quantity is also known as the coefficient of variation). To 
model variations in the measurement time, we sample simulation run times from a normal 
distribution (equation S34) with mean 72h and standard deviation 5h. We consider two cases: 
variations in cell seeding density alone and variations in both seeding density and measurement 
time. In both cases, we perform 105 control simulations (drug=0), divide the final cell counts into 
104 groups of 10, and calculate mean values for each group. We then perform 104 drug-treated 
simulations and take the ratio of all pairs of drug-treated and control values to give us 108 
samples of the static response ratio. Boxplots of these ratios are shown in Supplementary 
Figure 8b. Full distributions of <Xc(t)>, X(t), and the response ratio for variations in cell seeding 
density alone are shown in Supplementary Figure 8c, where analytical distributions (equations 
S30, S32, S33) are overlaid with simulation-based distributions. Simulation-based distributions 
in the case of variations in both cell seeding density and measurement time are shown in 
Supplementary Figure 8d.  
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Overall, we see that normally distributed variations in cell seeding density result in a 
significant distribution of response ratios and that variations in the measurement time act to 
skew this distribution towards larger values. As such, identical experimental setups can result in 
a wide range of response ratios, which are used to generate dose–response curves from which 
drug-response parameters are extracted. This variability may therefore explain, in part, reported 
discrepancies among drug-response parameters in different publicly-available datasets3,4. As 
emphasized above and in the main text, DIP rate does not suffer from such variability and, 
hence, its adoption as a standard drug effect metric may improve congruence among such 
datasets in the future. 
 
Variations in mean cell seeding density  
In addition to random variations in cell number around a mean seeding density (previous 
subsection), the absolute number of seeded cells can also greatly impact the dynamics of 
cellular proliferation and, hence, the precision and accuracy of measured values of drug effect 
metrics. The origin of this effect is the stochastic nature of cell fate decisions22,23, e.g., 
randomness in times to division and death. Such “intrinsic” stochastic effects are particularly 
prevalent at low cell numbers and, as a rule of thumb, scale as 1/√N, where N is the number of 
cells24. While a full theoretical treatment of the role of intrinsic stochasticity in cellular 
proliferation and its effect on drug effect metrics is outside the scope of this paper, we present in 
Supplementary Figure 9 results of an experimental investigation of variability in estimated DIP 
rates over a range of mean seeding densities. We treated populations of a BRAF-mutant 
melanoma cell line (SKMEL5) with 8 µM of the BRAF inhibitor PLX4720 for 150h and calculated 
DIP rates based on all data points ≳72h. Four time courses were obtained at each seeding 
density ranging from 312 to 10,000 cells/well (Supplementary Fig. 9a,b). As expected, the 
variance in the calculated DIP rates decreases with increasing seeding density (Supplementary 
Fig. 9c; Levene’s test p=0.0082). However, the mean values are statistically indistinguishable 
across seeding densities (p=0.47). These results indicate that reliable estimates of DIP rate can 
be obtained even at low seeding densities. 
 
Protocol for generating dose–response curves using DIP rate as the drug effect metric 
 
Needed: 
• Cells with genetically encoded nuclear label (e.g., H2BmCherry). 
• 96-well imaging plates (e.g., BD cat#353219). 
• Automated fluorescence microscope with 96-well plate-compatible stage (e.g., 
Synentec Cellavista, BD Pathway or Molecular Devices ImageXpress). 
• Drugs/compounds of interest. 
 
Method: 
1) Seed cells at ~2,500 cells per well in 96-well imaging plate and incubate overnight in 
environmentally controlled incubator. 
2) Prepare, in complete culture medium, eight four-fold dilutions of each drug (maximum 
= 4 µM, minimum = 0.24 nM). If prior knowledge exists of expected EC50 or IC50 (e.g. 
EC50 >> 250 nM, EC50 << 1 nM), adjust the range of concentrations accordingly. 
3) Replace medium in imaging plate with drug dilutions and two control wells receiving 
complete medium alone. Time of initial drug addition = 0. 
4) Obtain fluorescence microscopy images at least every 8–12h (hourly for more precise 
DIP rate estimate). 
5) Count cells for each time point and condition using digital image segmentation (e.g., 
ImageJ, Matlab, Python). 
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6) Structure data into a matrix containing seven columns: (1) time of measurement, (2) 
cell count, (3) cell line ID, (4) drug name, (5) drug concentration, (6) well number, and 
(7) date. 
7) Generate DIP rate-based dose–response curve by passing the data structure to 
dipDRC.r, an R function available at github.com/QuLab-VU/DIP_rate_NatMeth2016 
(see makeDRCexample.r for an example of usage). 
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SUPPLEMENTARY RESULTS 
 
 
Supplementary Figure 1 | Different formulations of the dose–response curve 
Potency parameters EC50 and IC50 are shown, as are area under the curve (AUC) and activity 
area (AA; the inverse of AUC), parameters that attempt to capture both potency and efficacy in 
a single quantity. (a) The “scaled” form given in equation (S2); (b) The “direct effect” form 
obtained by rearranging equation (S2) to solve for Edrug; (c) The “response ratio” form obtained 
by dividing the direct-effect form by E0. Note that we consider here a case where Emax < 0, which 
is possible when using a dynamic drug effect metric such as DIP rate. This results in IC50 < EC50 
(see equation S5). In cases like this, the IC50 is sometimes referred to as the GI50 (half-maximal 
growth inhibitory concentration; see Supplementary Table 1). 
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Supplementary Figure 2 | Fast-acting drugs, slow-acting drugs, and DIP rate 
Hypothetical growth curves (in log scale) for a cell line untreated and treated with two different 
drugs: a fast-acting drug where the full effect is achieved immediately, and a slow-acting drug 
that causes a temporal delay in the stabilization of the drug effect. Also shown is drug-induced 
proliferation (DIP) rate, defined as the slope of the line after the drug effect has stabilized (in this 
case, immediately for the fast-acting drug and ≥48h for the slow-acting drug). Note that the DIP 
rate is shown as equivalent for both the fast- and slow-acting drugs for illustration purposes 
only. 
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Supplementary Figure 3 | Two-state model of fractional proliferation predicts a sigmoidal 
relationship between proliferation rate and drug concentration. 
(a) The model assumes two states, a drug-naïve state and a drugged state, each with its own 
characteristic rate of proliferation (DIP0 and DIPmax, respectively), which is the difference 
between the rates of cell division and death. The rate of transition from the drug-naïve state to 
the drugged state depends on the concentration of drug, while the reverse transition does not. 
Hence, as the concentration of drug increases, the dynamic equilibrium between states shifts 
increasingly in favor of the drugged state. (b) Since the action of an antiproliferative drug is to 
reduce, and perhaps reverse, the rate of proliferation of a cell population, we assume that the 
proliferation rate of the drug-naïve state is positive and greater than that of the drugged state 
(which may be positive or negative). In Figure 1 of the main text, we assume that in each case 
the drug is cytotoxic at saturating drug concentrations (i.e., causes regression of the cell 
population). Hence, the DIP rate of the drugged state (DIPmax) is assumed to be negative. (c) An 
example dose–response curve predicted by the two-state model under the partial equilibrium 
assumption (PEA). The curve was generated from equation (S27) with EC50 = 1e–8 M, DIP0 = 
0.06*ln(2) h-1, and DIPmax = –0.03*ln(2) h-1. (d) An example dose–response curve predicted by 
the two-state model in conditions where the PEA does not hold. The curve was generated by 
numerical integration of equations (S12) and (S13) with kon = 1e5 M-1 h-1, koff = 1e–3 h-1, kdiv– 
kdeath = 0.06*ln(2) h-1, and kdiv* – kdeath* = –0.03*ln(2) h-1. Note that these are consistent with the 
values used in part (c); see equations (S22), (S23), and (S26). Arrows highlight largest 
differences between calculated values (circles) and the Hill equation fit (black line). 
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Supplementary Figure 4  | Theoretical illustration of bias in dose–response curves based 
on the NCI DTP dynamic drug effect metric 
(a) Growth curves in the absence and presence of 630 nM drug for the theoretical fast-growing 
cell line with delayed drug effect (Fig. 1c in the main text). Dash-dotted lines are a visual 
illustration of the NCI DTP dynamic metric and the time-dependent bias that it harbors. 
Depending on when cell count measurements are taken, the NCI DTP metric can indicate that 
the drug is partially cytostatic (<96h), fully cytostatic (96h), or cytotoxic (>96h) at this 
concentration. (b) Comparison of dose–response curves for this cell line and drug type based 
on the NCI DTP dynamic effect metric and DIP rate. The vertical orange line corresponds to 630 
nM drug concentration; circles correspond to those in part (a). 
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Supplementary Figure 5 | Static-based dose–response curves for PC9 parental cells and 
subclones treated with erlotinib 
Dose–response curves for three PC9-derived drug-sensitive (DS) clonal sublines (DS3, DS4, 
DS5) and parental PC9 cells treated with erlotinib using cell counts after 72h drug exposure as 
the drug effect metric. Filled circles are mean values (n ≥ 6), lines are optimal fits to a four-
parameter log-logistic model (equation S2), and grey shading indicates 95% confidence 
intervals on the fitting function. None of the dose–response curves for the clonal sublines is 
statistically different from the parental curve based on t-statistics and the null hypothesis that the 
ratio of clonal to parental values is 1 (p>0.05 for each of the four fitting parameters). 
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Supplementary Figure 6  | Automated estimation of DIP rate from cell count data 
Cell count data for the three PC9 sublines from Figure 2c of the main text is used to evaluate 
the ability to automatically estimate drug effect stabilization times and DIP rates using adjusted 
R2 and root-mean-squared error (RMSE) as measures of linearity. Best linear model fits to the 
population growth curves (solid red lines) are based on the RMSE-estimated stabilization times. 
A fifth-order polynomial (solid blue line) was fit to the RMSE curve and used to estimate the 
point at which exclusion of additional data points does not substantially improve the linear model 
fit. Source code implementing this approach (dipDRC.r) is freely available at 
github.com/QuLab-VU/DIP_rate_NatMeth2016. See Supplementary Note for more details. 
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Supplementary Figure 7  | Effects of sampling frequency on automated DIP rate 
estimation 
Cell count data for one PC9 subline (DS3) from Figure 2c of the main text is used to evaluate 
the robustness of the automated DIP rate estimation method to changes in sampling frequency. 
The full data set (top row) was successively subsampled a total of four times. Best linear model 
fits (solid red lines) are based on the adjusted R2-estimated stabilization times. DIP rates for 
data sets with ≥15 data points varied by less than 1%; DIP rate from the smallest data set (n=8) 
was within 15% of that for the full data set. Gray shading indicates 95% confidence interval on 
the DIP rate. See Supplementary Note and Supplementary Figure 6 for more details. 
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Supplementary Figure 8 | Theoretical effects of variations around a mean cell seeding 
density on the static effect metric and response ratio 
The two-state model of fractional proliferation (Supplementary Note and Supplementary Fig. 3) 
with the “fast proliferating / fast acting” parameter set (Supplementary Table 2) is seeded with 
initial cell counts drawn from a normal distribution with mean 1 and standard deviation 0.1 and 
simulated under untreated and drug-treated conditions. (a) 100 simulated time courses each of 
untreated and drug-treated cell populations. (b) Boxplots of static response ratios at 72h for 
variations in seeding density alone and variations in seeding density and measurement time (72 
± 5h). Based on 108 samples. Red line is the median; black dot is the mean; boxes extend from 
the first to third quartile; whiskers extend 1.5 times the interquartile range; outliers are not 
shown. (c) For variations in the seeding density alone, histograms for the mean of 10 untreated 
final (72h) cell counts (n=104; left column), the drug-treated final cell count (n=104; middle 
column), and the static response ratio (n=108; right column). Sample means, standard 
deviations, and skews are shown in each case. Analytical distributions are shown in red 
(equations S30, S32, and S33). (d) Same as c (less the analytical distributions) but for 
variations in both seeding density and measurement time (72 ± 5h). 
a 
c 
d 
b 
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Supplementary Figure 9 | Effects of variations in mean cell seeding density on DIP rate 
estimation 
Cell count data for BRAF-mutant (SKMEL5) melanoma cells treated with 8 µM PLX4720 is used 
to evaluate the effects of mean seeding density on DIP rate estimates. Cell counts were 
obtained using fluorescence microscopy imaging (Online Methods). (a) Population growth 
curves (log2 scaled) for each seeding density considered (n=4; seeding density is listed above 
each plot). Vertical dashed line corresponds to ~72h, the hand-chosen stabilization time; data to 
the right of this point were used to estimate DIP rate. (b) Population growth curves from part (a) 
normalized to the number of cells for each well at the first time point. Vertical dashed line 
corresponds to ~72h. (c) Boxplots of estimated DIP rates (n=4) at each seeding density. Mean 
values were statistically indistinguishable across all seeding densities (p=0.47); variances were 
not (Levene’s test25, p=0.0082), as expected (see Supplementary Note). 
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Supplementary Table 1 | Glossary of terms 
 
Activity	area	(AA)	 The	area	above	a	dose–response	curve	between	the	upper	(E0)	and	lower	(Emax)	plateaus3;	a	drug-activity	parameter	that	attempts	to	quantify	both	potency	and	efficacy	in	a	single	value;	the	inverse	of	the	AUC.	
Area	under	the	curve	(AUC)	 The	area	below	a	dose–response	curve	between	the	upper	(E0)	plateau	and	a	defined	lower	bound	(not	necessarily	the	lower	plateau	Emax);	a	drug-activity	parameter	that	attempts	to	quantify	both	potency	and	efficacy	in	a	single	value;	the	inverse	of	the	AA.	
Drug	activity	 General	term	for	the	action	of	a	drug	on	cells;	in	assays	of	cellular	proliferation,	refers	to	the	effect	that	a	drug	has	on	cell	division	and	death	(e.g.,	slowing	the	rate	of	progress	through	the	cell	cycle;	triggering	the	apoptotic	machinery).	
Drug-activity	parameter	 Any	quantified	value	that	can	be	extracted	from	a	dose–response	curve	(e.g.,	
Emax,	EC50,	GI50,	h,	IC50,	AA,	AUC).	
Drug	effect	 The	induced	response	of	a	population	of	cells	to	a	drug.	
Drug	effect	metric	 A	measured	value	that	quantifies	drug	effect	(e.g.,	cell	number	after	a	specified	period	of	drug	exposure,	DIP	rate).	
Drug-induced	proliferation	
(DIP)	rate	
The	steady-state	rate	of	expansion	or	regression	of	a	cell	population;	defined	in	terms	of	population	doublings	(log2-scaled	cell	numbers)	per	unit	time;	estimated	as	the	slope	of	the	line	on	a	plot	of	population	doublings	vs.	time	after	the	drug	effect	has	fully	stabilized;	a	proposed	metric	of	antiproliferative	drug	effect	in	vitro.	
Dynamic	metric	 	A	metric	whose	value	is	based	on	measurements	at	two	or	more	time	points	(e.g.,	DIP	rate,	NCI	DTP	metric).	
E0	 The	quantified	effect	in	the	absence	of	drug.	
Edrug	 The	quantified	effect	at	a	given	concentration	of	drug.	
Emax	 The	quantified	effect	at	saturating	drug	concentrations;	a	measure	of	efficacy1.	
EC50	 The	concentration	of	drug	at	which	the	effect	is	halfway	between	the	minimum	(E0)	and	maximum	(Emax)	effects;	a	measure	of	potency26.	
Efficacy	 The	degree	to	which	a	drug	can	produce	a	beneficial	effect.	
Fractional	proliferation	 The	concept	that	at	a	given	drug	concentration,	cells	experience	multiple	fates	(e.g.,	division,	death,	entry	into	quiescence)	and	that	the	cell	population	dynamics	are	a	combined	effect	of	all	of	these	events8.	
GI50	 The	concentration	of	drug	at	which	the	effect	is	50%	of	untreated	control	(E0/2),	independent	of	Emax;	technically	equivalent	to	IC50,	the	term	GI50	is	often	used	for	dose-response	curves	where	Emax	<	0	(refs	1	and	11);	a	measure	of	potency.	
h	 Hill	coefficient;	proportional	to	the	slope	of	the	dose–response	curve	at	x	=	
EC50;	shown	to	correlate	with	the	degree	of	heterogeneity	intrinsic	to	a	cell	line1.	
IC50	 The	concentration	of	drug	at	which	the	effect	is	50%	relative	to	untreated	control	(E0/2),	independent	of	Emax;	a	measure	of	potency1,4,27,28.	
Potency	 The	amount	of	drug	required	to	produce	a	specified	effect;	a	highly	potent	drug	is	active	at	low	concentrations.	
Response	ratio	 Ratio	of	the	quantified	effect	at	a	given	drug	concentration	(Edrug)	to	the	effect	in	the	absence	of	drug	(E0);	often	used	as	the	dependent	variable	in	dose–response	curves.	
Static	metric	 A	metric	whose	value	is	based	on	a	measurement	at	a	single	time	point	(e.g.,	cell	number	after	a	specified	period	of	drug	exposure).		
Time-dependent	bias	 Degree	to	which	the	value	of	a	metric	varies	with	the	chosen	measurement	time	point(s).	
Unbiased	metric	 A	metric	whose	value	is	independent	of	the	chosen	measurement	time	point(s)	(e.g.,	DIP	rate).	
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Supplementary Table 2 | Rate parameter values used in this work 
 
Parameter	
Theoretical	cell	type	/	drug	type	
Fast-proliferating	/		
Fast-acting	 Slow-proliferating	/		Fast-acting	 Fast-proliferating	/		Slow-acting	𝑘!"# − 𝑘!"#$! 	(h-1)	 0.06*ln(2)	 0.01*ln(2)	 0.06*ln(2)	𝑘!"#∗ − 𝑘!"#$!∗ 	(h-1)	 –0.03*ln(2)	 –0.005*ln(2)	 –0.03*ln(2)	𝑘!" 	(M-1	h-1)	 1e8†	 1e8†	 1e5	𝑘!"" 	(h-1)	 1†	 1†	 1e–3	
†These values were not set independently but as the ratio koff/kon (see equation S20). 
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